First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia
| dc.contributor.author | Valenzuela, Omar | |
| dc.contributor.author | Ibáñez, Sebastián | |
| dc.contributor.author | Poli, Cecilia | |
| dc.contributor.author | Roessler, Patricia | |
| dc.contributor.author | Aylwin, Mabel | |
| dc.contributor.author | Roizen, Gigia | |
| dc.contributor.author | Iruretagoyena, Mirentxu | |
| dc.contributor.author | Agar, Vivianne | |
| dc.contributor.author | Donoso, Javiera | |
| dc.contributor.author | Fierro, Margarita | |
| dc.contributor.author | Montes, José Miguel | |
| dc.date.accessioned | 2022-03-28T18:37:06Z | |
| dc.date.available | 2022-03-28T18:37:06Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Introduction/objectives: An interleukin-6 inhibition strategy could be effective in selected COVID-19 patients. The objective is to present our experience of tocilizumab use in patients with severe COVID-19. Methods: Observational retrospective cohort study. Hospitalized patients were evaluated by our multidisciplinary team for eventual use of tocilizumab. Patients with progressive ventilatory impairment and evidence of a hyperinflammatory state despite usual treatment received tocilizumab 8 mg/kg intravenous (maximum dose 800 mg), in addition to standard treatment. The use and time of use of mechanical ventilation (MV), the change of the Alveolar-arterial (A-a) gradient, of the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) and of inflammation laboratory parameters after 72 h of tocilizumab use was evaluated. Results: 29 patients received tocilizumab. 93.1% were men, 37.9% were obese, and 34.5% had hypertension. Of the 20 patients who were not on MV when receiving tocilizumab, 11 required non-invasive MV, for an average of 5 days, and one of them required intubation. A-a gradient, PaO2/FiO2, and inflammation parameters improved significantly. A better lymphocyte count, which improved significantly after tocilizumab use, was significantly associated with less use of MV. Five patients presented positive culture samples after tocilizumab, three being of clinical significance. A lower lymphocyte count was associated with having a positive culture. No other significant adverse events were seen. Conclusion: Our study suggests the utility and shows the safety of tocilizumab use in COVID-19 patients who have respiratory failure and evidence of hyperinflammation. Lymphocyte improvement was a predictor of good response. | es |
| dc.description.version | Versión Publicada | es |
| dc.identifier.citation | Valenzuela O, Ibáñez S, Poli MC, Roessler P, Aylwin M, Roizen G, Iruretagoyena M, Agar V, Donoso J, Fierro M, Montes J. First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia. Front Med (Lausanne). 2020 Nov 16;7:596916. doi: 10.3389/fmed.2020.596916. | es |
| dc.identifier.uri | https://doi.org/10.3389/fmed.2020.596916 | es |
| dc.identifier.uri | http://hdl.handle.net/11447/5829 | |
| dc.language.iso | en | es |
| dc.subject | Tocilizumab | es |
| dc.subject | Covid-19 | es |
| dc.subject | SARS-CoV 2 | es |
| dc.subject | Lymphocyte | es |
| dc.subject | Mechanical ventilalion | es |
| dc.title | First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia | es |
| dc.type | Article | es |
| dcterms.source | Frontiers in Medicine | es |